Feszak Igor Jarosław, Brzeziński Piotr, Feszak Sylwia, Kitowska Aleksandra, Waśkow Monika, Kawczak Piotr, Bączek Tomasz
Institute of Health Sciences, Pomeranian University in Słupsk, 76-200 Słupsk, Poland.
Department of Pediatrics, Pediatric Oncology, and Immunology, Pomeranian Medical University, 71-252 Szczecin, Poland.
J Clin Med. 2025 Sep 14;14(18):6473. doi: 10.3390/jcm14186473.
Oral isotretinoin remains the most effective therapy for severe acne, but its exceptional efficacy is often accompanied by relatively frequent adverse effects. In this study, we quantified the frequency- and dose-related predictors of clinical and biochemical adverse effects during isotretinoin treatment in routine Polish practice. The records of 370 patients (mean age: 28 ± 12 years) who began isotretinoin treatment between June 2020 and June 2025 were reviewed. The mean daily isotretinoin and cumulative isotretinoin doses were 23.4 ± 9.1 mg and 88.3 ± 31.5 mg/kg, respectively. The adverse events documented at two-monthly visits were correlated with age and dosing. Lipid, hepatic, thyroid and prolactin panels were compared with age- and sex-matched controls using χ statistics and odds ratios (ORs). Xerosis (70%), retinoid dermatitis (20%) and cheilitis (15.5%) predominated. Hand eczema rose with higher daily isotretinoin doses (ρ = 0.082; = 0.037), whereas pruritus declined with greater cumulative isotretinoin exposure (ρ = -0.088; = 0.037). Retinoid dermatitis was linked to a younger age (ρ = -0.080; = 0.0286), whereas desquamation increased slightly with age (ρ = +0.083 = 0.0228). Overall, dyslipidemia was twice as common as in the controls (OR: 2.06; 95% CI: 1.49-2.86; -value: <0.0001), which was driven by an elevated total cholesterol (OR: 1.93; 95% CI: 1.34-2.77; -value: 0.0004), LDL (OR: 3.40; 95% CI: 2.26-5.10; -value: <0.0001) and triglycerides (OR: 1.95; 95% CI: 1.20-3.17; -value: 0.0062) and decreased HDL (OR: 2.68; 95% CI: 1.75-4.10; -value: <0.0001). Interestingly, hyperprolactinemia occurred eight-fold more often (OR: 8.42; 95%; 95% CI: 2.97-23.84; -value: <0.00001). Aminotransferase and TSH elevations were infrequent and statistically non-significant. At moderate cumulative doses, isotretinoin was generally well tolerated; however, clinically relevant lipid and prolactin disturbances were frequent. Routine lipid and endocrine monitoring, early emollient prophylaxis and dose individualization are recommended to ensure safe isotretinoin usage in everyday practice.
口服异维A酸仍然是治疗重度痤疮最有效的方法,但其卓越疗效往往伴随着相对频繁的不良反应。在本研究中,我们对波兰常规临床实践中异维A酸治疗期间临床和生化不良反应的频率及剂量相关预测因素进行了量化。回顾了2020年6月至2025年6月开始接受异维A酸治疗的370例患者(平均年龄:28±12岁)的记录。异维A酸的平均日剂量和累积剂量分别为23.4±9.1mg和88.3±31.5mg/kg。每两个月随访记录的不良事件与年龄和剂量相关。使用χ统计量和比值比(OR)将血脂、肝脏、甲状腺和催乳素指标与年龄和性别匹配的对照组进行比较。皮肤干燥(70%)、类维生素A皮炎(20%)和唇炎(15.5%)最为常见。手部湿疹随异维A酸日剂量增加而增多(ρ=0.082;P=0.037),而瘙痒随异维A酸累积暴露量增加而减少(ρ=-0.088;P=0.037)。类维生素A皮炎与年龄较小有关(ρ=-0.080;P=0.0286),而脱屑随年龄略有增加(ρ=+0.083;P=0.0228)。总体而言,血脂异常的发生率是对照组的两倍(OR:2.06;95%CI:1.49-2.86;P值:<0.0001),这是由总胆固醇升高(OR:1.93;95%CI:1.34-2.77;P值:0.0004)、低密度脂蛋白(OR:3.40;95%CI:2.26-5.10;P值:<0.0001)和甘油三酯升高(OR:1.95;95%CI:1.20-3.17;P值:0.0062)以及高密度脂蛋白降低(OR:2.68;95%CI:1.75-4.10;P值:<0.0001)所致。有趣的是,高催乳素血症的发生率高出八倍(OR:8.42;95%;95%CI:2.97-23.84;P值:<0.00001)。转氨酶和促甲状腺激素升高不常见且无统计学意义。在中等累积剂量下,异维A酸总体耐受性良好;然而,临床上相关的血脂和催乳素紊乱较为常见。建议进行常规血脂和内分泌监测、早期润肤预防以及剂量个体化,以确保在日常实践中安全使用异维A酸。